SUCCESSFUL USE OF RECOMBINANT FVIIa (NOVOSEVEN<sup>®</sup>) IN THE MANAGEMENT OF INTRACTABLE POST‐SURGICAL INTRA‐ABDOMINAL HAEMORRHAGE

White,; McHale,; Ravi,; Reynolds,; Stephens,; Moriarty,; Smith, Stacy

doi:10.1046/j.1365-2141.1999.01798.x

Cited by 110 publications

(50 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They include a report of 2 patients with Crohn's disease who suffered severe postsurgical intra-abdominal haemorrhage [2]. The patients, a 22-year-old woman and a 62-year-old man, presented with massive lower gastrointestinal bleeding requiring colectomy.…”

Section: Rfviia In Noncardiac Surgerymentioning

confidence: 99%

The Use of Recombinant Factor VIIa in Controlling Surgical Bleeding in Non-Haemophiliac Patients

Aldouri

2002

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

Recombinant factor VIIa (rFVIIa, NovoSeven^®) is effective and appears safe in the management of bleeding episodes and provision of surgical cover in haemophilia patients with inhibitors. Additionally, rFVIIa has been considered as a universal haemostatic agent, prompting its use in the management of severe uncontrolled surgical bleeding in patients without pre-existing coagulopathies. Recombinant FVIIa has been used in 5 patients (aged 2.5 to 73.0 years; median 48 years) with uncontrolled bleeding during or after open-heart surgery. Satisfactory haemostasis was achieved with a single dose or rFVIIa 30 µg/kg, that resulted in reduction of blood loss from a mean of 4,170 ml (650–8,000 ml) to 262.5 ml (220–334 ml). No significant adverse events were reported. Recombinant FVIIa was also successfully used in controlling post-surgical bleeding in two patients with Crohn’s disease, one patient with bleeding duodenal ulcer and another with false thoracic aneurysm. It was also effective in controlling bleeding post-splenectomy in a patient with chronic myeloid leukaemia, and following anterior exenteration in a patient with cervical carcinoma. A randomised study comparing the efficacy of a single perioperative dose of rFVIIa with placebo in patients undergoing transabdominal prostatectomy was conducted by Levi and colleagues [6]. An interim analysis showed a significant reduction in mean blood loss from 2,450 ± 350 ml to 1,400 ± 190 ml between placebo and rFVIIa groups respectively (p = 0.007). Among trauma patients, Kenet et al. reported success in treating uncontrolled bleeding from a gun-shot wound to the inferior vena cava, using two doses of rFVIIa 60 µg/kg [7]. This treatment has subsequently been used in 6 surgical patients with uncontrolled bleeding and in 7 cases of traumatic bleeding, with remarkable results. In conclusion, rFVIIa appears to be effective and safe in the management of uncontrolled surgical and traumatic haemorrhage in patients not known to have inherited coagulopathy.

show abstract

Section: Rfviia In Noncardiac Surgerymentioning

confidence: 99%

The Use of Recombinant Factor VIIa in Controlling Surgical Bleeding in Non-Haemophiliac Patients

Aldouri

2002

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

show abstract

“…In den letzten Jahren wurde rFVIIa erfolgreich in zahlreichen Fällen traumatischer und chirurgischer Blutungen eingesetzt [26,36]. Rekombinanter aktivierter Faktor VIIa wirkt in Gegenwart von "tissue factor": Startpunkt der Gerinnung ist die Bindung und Aktivierung von Faktor VII durch Bindung an Tissue factor auf der Oberfläche subendothelialer Zellen.…”

Section: Rekombinanter Aktivierte Faktor Viia (Novoseven®)unclassified

Gerinnungsmanagement beim Polytrauma

et al. 2005

View full text Add to dashboard Cite

Hemorrhage after traumatic injury results in coagulopathy which only worsens the situation. This coagulopathy is caused by depletion and dilution of clotting factors and platelets, increased fibrinolytic activity, hypothermia, metabolic changes and anemia. The effect of synthetic colloids used for compensating the blood loss, further aggravates the situation through their specific action on the hemostatic system. Bedside coagulation monitoring permits relevant impairment of the coagulation system to be detected very early and the efficacy of the hemostatic therapy to be controlled directly. Administration of fresh frozen plasma (FFP), platelet concentrates and antifibrinolytic agents is essential for restoring the impaired coagulation system in trauma patients. Clotting factor concentrates should be administered if coagulopathy is based on diagnosed depletion of clotting factors, if FFP is not available and if transfusion of FFP is insufficient to treat the coagulopathy. Recombined FVIIa is frequently employed during severe bleeding which could not be treated by conventional methods but the results of on-going clinical trials are not yet available.

show abstract

“…19 A 22-year-old female with Crohn's disease presented with a massive lower GI hemorrhage requiring emergent resection. She had no history of a bleeding disorder and had normal preoperative studies including platelet count, PT and APTT.…”

Section: Gi Hemorrhage and Crohn's Diseasementioning

confidence: 99%

The Use of Recombinant Factor VIIa in Gastrointestinal Bleeding

Parameswaran

Shapiro

2003

Transfus Alt Transfus Med

View full text Add to dashboard Cite

SUCCESSFUL USE OF RECOMBINANT FVIIa (NOVOSEVEN^®) IN THE MANAGEMENT OF INTRACTABLE POST‐SURGICAL INTRA‐ABDOMINAL HAEMORRHAGE

Abstract: Ò) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukaemia and acquired FVII de®ciency. British Journal of Haematology, 106, 254± 255.

Cited by 110 publications

References 4 publications

The Use of Recombinant Factor VIIa in Controlling Surgical Bleeding in Non-Haemophiliac Patients

The Use of Recombinant Factor VIIa in Controlling Surgical Bleeding in Non-Haemophiliac Patients

Gerinnungsmanagement beim Polytrauma

The Use of Recombinant Factor VIIa in Gastrointestinal Bleeding

Contact Info

Product

Resources

About

SUCCESSFUL USE OF RECOMBINANT FVIIa (NOVOSEVEN®) IN THE MANAGEMENT OF INTRACTABLE POST‐SURGICAL INTRA‐ABDOMINAL HAEMORRHAGE

Abstract: Ò) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukaemia and acquired FVII de®ciency. British Journal of Haematology, 106, 254± 255.

Cited by 110 publications

References 4 publications

The Use of Recombinant Factor VIIa in Controlling Surgical Bleeding in Non-Haemophiliac Patients

The Use of Recombinant Factor VIIa in Controlling Surgical Bleeding in Non-Haemophiliac Patients

Gerinnungsmanagement beim Polytrauma

The Use of Recombinant Factor VIIa in Gastrointestinal Bleeding

Contact Info

Product

Resources

About

SUCCESSFUL USE OF RECOMBINANT FVIIa (NOVOSEVEN^®) IN THE MANAGEMENT OF INTRACTABLE POST‐SURGICAL INTRA‐ABDOMINAL HAEMORRHAGE